Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors

INTRODUCTION: In this study, we aim to report the outcome of COVID-19 in chronic myeloid leukemia (CML) patients receiving tyrosine kinase inhibitor (TKI). METHOD: The data of 16 laboratory-confirmed COVID-19 patients with CML receiving TKI and age, gender, and comorbid disease matched COVID-19 pati...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Oncol Pharm Pract
Autori principali: Başcı, Semih, Ata, Naim, Altuntaş, Fevzi, Yiğenoğlu, Tuğçe Nur, Dal, Mehmet Sinan, Korkmaz, Serdal, Namdaroğlu, Sinem, Baştürk, Abdülkadir, Hacıbekiroğlu, Tuba, Doğu, Mehmet Hilmi, Berber, İlhami, Dal, Kürşat, Erkurt, Mehmet Ali, Turgut, Burhan, Çağlayan, Murat, Ayvalı, Mustafa Okan, Çelik, Osman, Ülgü, Mustafa Mahir, Birinci, Şuayip
Natura: Artigo
Lingua:Inglês
Pubblicazione: SAGE Publications 2020
Soggetti:
Original Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7506180/
https://ncbi.nlm.nih.gov/pubmed/32854573
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1078155220953198
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi